Viridian Therapeutics, Inc.\DE (VRDN)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $348k
- Aug 19 · Unusual
- Form 4 sales
- 23
- On record
- Form 144 notices
- 6
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planJun 16 2023
Sold 2,296 shares at $28.02 ($64k)
Meisner Lara, Chief Legal Officer
No 10b5-1 planSold 7.1% of holdings ($904k position)29,971 shares left0.3x usual sizeFollows a Form 144Filing
- 2 Form 144 noticeNoticeNov 16 +153 days
Filed to sell 35,368 shares ($535k)
Myers Scott Dunseth, Former Officer and Director
No 10b5-1 planFirst sale on recordFiling
- 3 Form 144 noticeNoticeDec 1 +15 days
Filed to sell 3,125 shares ($53k)
Meisner Lara, Former Officer
No 10b5-1 plan0.4x usual sizeFiling
- 4 Form 144 noticeNoticeDec 7 +6 days
Filed to sell 24,900 shares ($471k)
Humer Kristian, Former Officer
No 10b5-1 planFirst sale on recordFiling
- 5 Form 144 noticeNoticeDec 12 +5 days
Filed to sell 252,600 shares ($4.3M)
Humer Kristian, Former CFO
No 10b5-1 planFirst sale on recordFiling
- 6 Form 144 noticeNoticeDec 18 +6 days
Filed to sell 9,375 shares ($198k)
Meisner Lara, Former Officer
No 10b5-1 plan1.2x usual sizeFiling
- 7 Form 4 saleUnusualDec 31 +744 days
Sold 2,272 shares at $31.16 ($71k)
Tousignant Jennifer, Chief Legal Officer
No 10b5-1 planSold 100% of holdings ($71k position)0 shares leftFirst sale on recordFiling
- 8 Form 4 saleUnusualAug 19 +231 days
Sold 14,212 shares at $24.50 ($348k)
Tousignant Jennifer, Chief Legal Officer
No 10b5-1 planSold 100% of holdings ($348k position)0 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (29)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Tousignant Jennifer | Chief Legal Officer | Form 4 sale | 14,212 | $348k | 100.0% | Unusual | SEC |
| Dec 31, 2025 | Tousignant Jennifer | Chief Legal Officer | Form 4 sale | 2,272 | $71k | 100.0% | Unusual | SEC |
| Dec 18, 2023 | Meisner Lara | Former Officer | Form 144 notice | 9,375 | $198k | Notice | SEC | |
| Dec 12, 2023 | Humer Kristian | Former CFO | Form 144 notice | 252,600 | $4.3M | Notice | SEC | |
| Dec 7, 2023 | Humer Kristian | Former Officer | Form 144 notice | 24,900 | $471k | Notice | SEC | |
| Dec 1, 2023 | Meisner Lara | Former Officer | Form 144 notice | 3,125 | $53k | Notice | SEC | |
| Nov 16, 2023 | Myers Scott Dunseth | Former Officer and Director | Form 144 notice | 35,368 | $535k | Notice | SEC | |
| Jun 16, 2023 | Meisner Lara | Chief Legal Officer | Form 4 sale | 2,296 | $64k | 7.1% | No plan | SEC |
| Jun 6, 2023 | Meisner Lara | Chief Legal Officer | Form 4 sale | 7,500 | $186k | 20.0% | Routine | SEC |
| Jun 2, 2023 | Meisner Lara | Officer | Form 144 notice | 12,469 | $305k | Notice | SEC | |
| Mar 9, 2023 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 29,971 | $871k | 100.0% | Unusual | SEC |
| Feb 2, 2023 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 50,000 | $1.8M | 10.4% | Plan not stated | SEC |
| Jan 23, 2023 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 6,843 | $244k | 100.0% | Unusual | SEC |
| Jan 17, 2023 | Katz Barrett | Chief Medical Officer | Form 4 sale | 29,000 | $1.1M | 100.0% | Unusual | SEC |
| Jan 10, 2023 | Katz Barrett | Chief Medical Officer | Form 4 sale | 60,000 | $2.1M | 100.0% | Unusual | SEC |
| Dec 21, 2022 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 16,926 | $493k | 100.0% | Unusual | SEC |
| Dec 16, 2022 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 1,597 | $45k | 100.0% | Unusual | SEC |
| Dec 14, 2022 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 16,256 | $457k | 100.0% | Unusual | SEC |
| Nov 15, 2022 | Meisner Lara | General Counsel and Secretary | Form 4 sale | 8,125 | $179k | 100.0% | Unusual | SEC |
| Jun 1, 2022 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 30,000 | $366k | 5.9% | Plan not stated | SEC |
| May 2, 2022 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 30,000 | $391k | 5.5% | Plan not stated | SEC |
| Apr 4, 2022 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 30,000 | $568k | 5.3% | Plan not stated | SEC |
| Mar 2, 2022 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 30,000 | $529k | 5.0% | Plan not stated | SEC |
| Feb 3, 2022 | Violin Jonathan | Chief Executive Officer | Form 4 sale | 30,000 | $573k | 4.8% | Plan not stated | SEC |
| Dec 20, 2017 | Hughes Thomas E. | Director | Form 4 sale | 12,000 | $96k | 80.9% | Unusual | SEC |
| Mar 10, 2017 | Lefkoff Kyle | Director | Form 4 sale | 5,800 | $83k | 1.2% | Plan not stated | SEC |
| Mar 8, 2017 | Lefkoff Kyle | Director | Form 4 sale | 15,000 | $231k | 3.1% | Plan not stated | SEC |
| Feb 28, 2017 | Lefkoff Kyle | Director | Form 4 sale | 10,258 | $143k | 2.1% | Plan not stated | SEC |
| Feb 23, 2017 | Lefkoff Kyle | Director | Form 4 sale | 5,902 | $83k | 1.2% | Plan not stated | SEC |